Welcome to CDC stacks |
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
National Shortage of Purified-Protein Derivative Tuberculin Products
  • Published Date:
    Apr 26 2013
  • Source:
    MMWR Morb Mortal Wkly Rep. 2013; 62(16):312.
  • Language:
    English
Filetype[PDF-94.20 KB]


Details:
  • Alternative Title:
    MMWR Morb Mortal Wkly Rep
  • Description:
    Tubersol, a product of Sanofi Pasteur Limited, is in short supply nationwide until at least the end of May 2013. Tubersol is one of two purified-protein derivative (PPD) tuberculin products licensed by the Food and Drug Administration (FDA). The manufacturer has notified CDC that 50-dose vials of Tubersol will remain unavailable until the end of May 2013 and that supplies of 10-dose vials are still being reestablished: the product is available only by contacting Sanofi directly (at https://www.vaccineshoppe.com/index.cfm? or telephone, 800-822-2463). JHP Pharmaceuticals, LLC, the manufacturer of Aplisol, the other PPD tuberculin product licensed by FDA, has notified FDA that the product is available in restricted quantity. Acute local shortages of Aplisol also have been reported to CDC by TB control officials, as health-care providers switch from Tubersol to Aplisol. The shortages of Aplisol probably will diminish as Tubersol supplies are restored to their preshortage availability in the normal distribution networks. This report advises public health officials, clinicians, and workers in occupational health and infection control about how to adapt to the shortage.

  • Pubmed ID:
    23615675
  • Pubmed Central ID:
    PMC4604962
  • Document Type:
  • Place as Subject:
  • Main Document Checksum:
No Related Documents.
You May Also Like: